FTI Consulting Boosts Health Solutions Practice With Two New Executives

FTI Consulting (FTI) announced the appointment of two new executives to its Health Solutions practice, bringing in Jacinthe Guindon as a Managing Director and Anthony Gotzis as a Senior Managing Director in the firm’s Life Sciences division.

The Washington, D.C. headquartered FTI Consulting was founded in 1982 and has served as trusted advisor to a wide variety of public and private sector clients around the world, offering services such as corporate finance and restructuring, forensic and litigation consulting, economic consulting, technology, strategic communications, and life sciences consulting.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

“Our clients in the life sciences industry look to us to solve their biggest business challenges,” Charles Overstreet, Global Leader of the Health Solutions practice at FTI Consulting, said in a statement. “Anthony and Jacinthe, who have more than 60 years of combined experience in the life sciences industry, will bring real-world knowledge and innovative ideas to our clients who are navigating an increasingly complex environment.”

Anthony Gotzis is based in Philadelphia and has spent almost three decades providing advisory services to clients spread across nearly all sectors of the life sciences industry. His professional experience includes leading the implementation of large transformation initiatives to mitigate risk and drive operational efficiencies. Over the course of his career he has developed and led multiple consulting practices serving the life sciences industry. Gotzis’ role as Senior Managing Director will see him leading the Life Sciences R&D and Quality capability team within FTI’s Life Sciences arm.

Toronto-based Jacinthe Guindon brings more than 30 years of experience in all aspects of clinical development, spanning medical devices, pharmaceuticals, and biopharmaceuticals in the United States and Canada. Guindon has managed safety monitoring committees, clinical and scientific advisory boards, and has served as a key member of M&A teams. During her tenure at various biotech and pharma companies, she has directed the end-to-end development of many therapeutics in both the United States and Canada.

FTI’s Life Sciences offering provides world-class capabilities across biotechnology, medical device and diagnostics, and pharmaceuticals to help clients solve their most complex challenges while helping shape the technology that will improve the lives of providers, patients, and communities.